SCHEMBL15050009

SCHEMBL15050009

Cc1nc2ccc(C(=O)N3CCNCC3)cn2c1-c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL1 P55085 1/20 0.68
SIGMAR1 Q99720 1/20 0.50
MKNK1 Q9BUB5 4/20 0.47
MKNK2 Q9HBH9 4/20 0.47
EIF4E P06730 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
CCNC P24863 4/20 0.43
CDK8 P49336 4/20 0.43
SLC6A7 Q99884 1/20 0.42
HPGD P15428 1/20 0.41
AKT1 P31749 1/20 0.41
AKT2 P31751 1/20 0.41
TLR9 Q9NR96 1/20 0.41
TLR8 Q9NR97 1/20 0.41
TLR7 Q9NYK1 1/20 0.41
SLC2A1 P11166 1/20 0.41
ATR Q13535 1/20 0.41
POLB P06746 1/20 0.40
RIPK1 Q13546 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL15049976 0.99 F2RL1 (0.67) F2RL1SIGMAR1MKNK1MKNK2EIF4E
SCHEMBL15071152 0.90 F2RL1 (0.75) F2RL1MKNK1MKNK2SLC6A7HPGD
SCHEMBL15071100 0.88 F2RL1 (0.77) F2RL1SLC6A7HPGDAKT1AKT2
SCHEMBL31518 0.87 F2RL1 (0.72) F2RL1MKNK1MKNK2EIF4ESLC6A7
SCHEMBL15071143 0.86 F2RL1 (0.74) F2RL1MKNK1MKNK2SLC6A7HPGD
SCHEMBL15071158 0.85 F2RL1 (0.73) F2RL1ADORA2AHPGD
SCHEMBL15071160 0.84 F2RL1 (0.67) F2RL1SLC6A7HPGDAKT1AKT2
SCHEMBL31526 0.84 F2RL1 (0.90) F2RL1HPGDSLC2A1
SCHEMBL15074832 0.83 F2RL1 (0.69) F2RL1HPGDAKT1AKT2
SCHEMBL15071154 0.83 F2RL1 (0.66) F2RL1SLC6A7AKT1AKT2SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2617721-A2 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME Neopharm Co., Ltd. (KR) 2013-07-24 EP disclosed
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME NEOPHARM CO.,LTD. (KR) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME F2RL1, F2R, FPR2 F2RL1 1/4885SIGMAR1 3828/4885MKNK1 1943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.